Militia Capital Management LLC Purchases New Holdings in iShares Biotechnology ETF $IBB

Posted by Max Byerly on Jul 23rd, 2026

Militia Capital Management LLC bought a new stake in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) in the 1st quarter, Holdings Channel reports. The firm bought 24,100 shares of the financial services provider’s stock, valued at approximately $4,069,000. iShares Biotechnology ETF accounts for about 0.9% of Militia Capital Management LLC’s portfolio, making the stock its 19th largest holding.

Several other large investors have also bought and sold shares of IBB. Basepoint Wealth LLC purchased a new stake in iShares Biotechnology ETF during the 4th quarter valued at $26,000. Cary Street Partners Financial LLC bought a new position in iShares Biotechnology ETF in the 4th quarter worth $29,000. Darwin Wealth Management LLC purchased a new position in iShares Biotechnology ETF in the 2nd quarter worth approximately $25,000. Caitlin John LLC purchased a new stake in iShares Biotechnology ETF in the 4th quarter worth $34,000. Finally, Cornerstone Planning Group LLC bought a new position in shares of iShares Biotechnology ETF during the 4th quarter valued at about $35,000. 62.45% of the stock is owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Stock Down 1.2%

Shares of IBB opened at $187.00 on Thursday. iShares Biotechnology ETF has a 1 year low of $130.25 and a 1 year high of $199.05. The business’s 50 day simple moving average is $178.75 and its 200-day simple moving average is $173.81.

iShares Biotechnology ETF Cuts Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 18th. Investors of record on Monday, June 15th were given a $0.0238 dividend. The ex-dividend date was Monday, June 15th. This represents a $0.10 annualized dividend and a yield of 0.1%.

About iShares Biotechnology ETF

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.